Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer.

Abstract

A multicentre, double-blind, randomized, placebo-controlled trial was undertaken to investigate the therapeutic efficacy of a nocturnal dose of famotidine 20 mg to reduce the 1 year relapse rate of recently healed gastric ulcers. Twenty investigators in eight countries randomized 202 patients with endoscopically confirmed healed gastric ulcers. Repeat endoscopies were performed at 6 and 12 months or for symptoms compatible with ulcer relapse. A per protocol analysis of cumulative life table relapse at 12 months showed that famotidine 20 mg was superior to placebo in reducing gastric ulcer relapse, 24 versus 50%, respectively (P less than 0.01). Both placebo and famotidine were well tolerated. Since nocturnal dosing with famotidine 20 mg is effective in preventing gastric ulcer relapse over a 1-year period and is well tolerated, it offers a therapeutic option for the long-term treatment of patients with gastric ulcer.

• Authors: R G Berlin, J K Root, T J Cook
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 5 Issue 2 Pg. 161-71 (Apr 1991) ISSN: 0269-2813 [Print] England
• PMID: 1888817 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Famotidine

Topics

• Adult
• Double-Blind Method
• Famotidine (administration & dosage, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Recurrence
• Stomach Ulcer (prevention & control)